scholarly journals Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives

2018 ◽  
Vol 19 (8) ◽  
pp. 2332 ◽  
Author(s):  
Altaf Mohammed ◽  
Nagendra Sastry Yarla ◽  
Venkateshwar Madka ◽  
Chinthalapally V. Rao
Keyword(s):  
Colon Cancer ◽  
Cancer Chemoprevention ◽  
Chemopreventive Agents ◽  
Early Stages ◽  
Drug Classes ◽  
Recent Advancement ◽  
Preclinical Trials ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Further Development

Substantial efforts are underway for prevention of early stages or recurrence of colorectal cancers (CRC) or new polyp formation by chemoprevention strategies. Several epidemiological, clinical and preclinical studies to date have supported the chemopreventive potentials of several targeted drug classes including non-steroidal anti-inflammatory drugs (NSAIDs) (aspirin, naproxen, sulindac, celecoxib, and licofelone), statins and other natural agentsboth individually, and in combinations. Most preclinical trials although were efficacious, only few agents entered clinical trials and have been proven to be potential chemopreventive agents for colon cancer. However, there are limitations for these agents that hinder their approval by the food and drug administration for chemoprevention use in high-risk individuals and in patients with early stages of CRC. In this review, we update the recent advancement in pre-clinical and clinical development of selected anti-inflammatory agents (aspirin, naproxen, sulindac, celecoxib, and licofelone) and their combinations for further development as novel colon cancer chemopreventive drugs. We provide further new perspectives from this old research, and insights into precision medicine strategies to overcome unwanted side-effects and overcoming strategies for colon cancer chemoprevention.

scholarly journals O USO DE ANTIINFLAMATÓRIOS ESTEROIDAIS E NÃO ESTERIODAIS NO CONTROLE DA DOR E DO EDEMA EM CIRURGIA DE TERCEIROS MOLARES

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Ricardo Natã Fonseca Silva ◽  
Lúcia Coelho Garcia Pereira
Keyword(s):  
Literature Review ◽  
Oral Cavity ◽  
Postoperative Period ◽  
Dental Arch ◽  
Third Molars ◽  
Drug Classes ◽  
Surgical Extraction ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Congenitally Missing

Introduction: Third molars are the last teeth to erupt through the oral cavity and in some cases they are congenitally missing, display impaction or remain included. There are many reasons for their removal: decay, lack of space in the dental arch or problems during its eruption. During surgical extraction, oral tissues may be injured, which causes painful symptoms and edema. To combat these surgical complications, it is necessary the use of drugs that fight inflammation, non-steroidal anti-inflammatory drug (NSAIDs) and corticosteroids. To obtain best results, the combination of NSAIDs and steroidal anti-inflammatory drugs are used in patients, either as preemptive medication and as postoperative medication. Objective: Performing a literature review in order to determine which drug classes have better postoperative outcomes for pain and swelling in of third molars extraction. Materials and methods: Studies present in SciELO, Lilacs and Pubmed databases published between 2000-2014 were included. Final considerations: Corticosteroids are used preemptively in order to reduce swelling frame, while NSAIDs have greater use in the postoperative period, in an attempt to reduce the pain.

Sign in / Sign up

Export Citation Format

Share Document